October 15, 2019 8:30am
In this pricing marathon, an upside market could carry “our’ universe across today’s session’s finish line
For my universe, October has registered 4 positive, 1 neutral and 6 negative close, so far …
News: CRISPR Therapeutics (CRSP) and KSQ Therapeutics, a biotechnology company using CRISPR technology announced a license agreement whereby CRSP will gain access to KSQ IP for editing certain novel gene targets in its allogeneic oncology cell therapy programs, and KSQ will gain access to CRSP IP for editing novel gene targets identified by KSQ as part of its current and future eTIL™ (engineered tumor infiltrating lymphocyte) cell programs. The financial terms of the agreement are NOT being disclosed.
Insight is about understanding perception and is putting into context what is relevant to expectation fulfillment …
But cannot be imaginative in considering explanations for missing, confusing and often contradictory data while human analysis is able to identify one’s own biases and expectation of what the data might/should/could show!
Dow futures are UP +0.32% (+85 points), S&P futures are UP +0.32% (+10 points) and NASDAQ futures are UP +0.31% (+25 points)
U.S. stock index futures were higher Tuesday morning, after a number of major companies posted big earnings beats;
European stocks rose after European Union negotiator Michel Barnier said a Brexit deal between the bloc and the U.K. is still possible this week while the pan-European Stoxx 600 slightly pared early gains to trade +0.5% higher by mid-morning;
Asia Pacific markets traded cautiously following the previous day’s rally, as new doubts emerged overnight about the U.S.-China partial trade deal;
Data docket: the New York Empire State manufacturing figures are due to be released at 8:30 a.m. ET.
The “machines” and algorithms should be powered-up for the depreciated, oversold cell and gene therapy RegMed universe.
Earnings season kicked off with stronger-than-expected results from J.P. Morgan Chase, Johnson & Johnson, UnitedHealth, and BlackRock, sending shares higher in the premarket. Shares of Goldman Sachs fell, however, after its earnings missed Street estimates. Citigroup and Wells Fargo will release their latest performance numbers before the bell, while United Airlines and Interactive Brokers will release earnings after the bell<CNBC>.
10/23 begins the advent of cell and gene therapy conference calls!
Monday night’s newsletter heading: “what’s in play? Sentiment, low volume, percentage change, momentum, sustainability and the list goes on especially with Q3 results about to be released. What’s rife is speculation versus any buyers delight in possessing a “comer”. “Like a story” today and its trending pricing and momentum and it’s a next day or week’s dog
- The NASDAQ closed down -8.39 points (-0.10%)
- The IBB closed up +0.38% while the XBI closed down -0.18%;
- The close was negative with an A/D line of 12/28, 2 flats, 1 reversed merged (HSGX) and 2 acquired;
- The range of the 12 upside was +0.22% (ALNY) to +15.12% (ADVM) while the 28 downside ranged from -0.09% (GBT) to -14.67% (RENE.L);
- 3 out of the 12 upside had higher than the 3 month average volume;
- 2 out of the 28 downside had higher than the 3 month average volume;
- October registered 4 positive, 1 neutral and 6 negative close, so far …
- September, there were 1 holiday, 11 negative, 7 positive and 2 non reported sessions;
Companies in my headlights – It’s your decision; I provide an idea and context:
*** I’m STILL following the trading herd but … mindful of upcoming quarterly results and their effect upon share pricing … BUY and get trampled in the coming sessions or SELL into strength or just HOLD and wait to resolve relieve the anxiety until value returns.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.